Tamara Weiss

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Daniela Cilloni, Aline Renneville, Fabienne Hermitte et al. · Journal of Clinical Oncology · 2009 · 434 citations · Full text

Medicine, Hematology, Oncology +17

Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML

Susanne Schnittger, Wolfgang Kern, Claudia Tschulik et al. · Blood · 2009 · 327 citations · Full text

Medicine, Oncology, Pathology +10

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in <i>TET2</i>, <i>CBL</i>, <i>RAS</i>, and <i>RUNX1</i>

Alexander Kohlmann, Hans‐Ulrich Klein, Sonja Schindela et al. · Journal of Clinical Oncology · 2010 · 290 citations

Medicine, Genetics, Hematology +17

Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC)

Miriam Miesner, Claudia Haferlach, Ulrike Bacher et al. · Blood · 2010 · 125 citations · Full text

Medicine, Hematology, Oncology +17

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)

Brunangelo Falini, Katja Macijewski, Tamara Weiss et al. · Blood · 2010 · 121 citations · Full text

Medicine, Oncology, Pathology +5